- Home
- QLGN
as 10-28-2025 2:05am EST
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | CALIFORNIA |
| Market Cap: | 7.4M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 3.7M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.61 - $8.81 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Qualigen Therapeutics Inc. News
QLGN Breaking Stock News: Dive into QLGN Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Top Premarket Gainers
GlobeNewswire
5 days ago
Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation
GlobeNewswire
15 days ago
Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?
GlobeNewswire
22 days ago
Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FX Finalizes U.S. Production Assembly Plan
MT Newswires
5 months ago
Qualigen Therapeutics Receives Nasdaq Deficiency Notice
GlobeNewswire
5 months ago
Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
GlobeNewswire
6 months ago
Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K
GlobeNewswire
7 months ago
Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme
Compare QLGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QLGN Qualigen Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.